Momentum Biotechnologies
Peter Rye is a highly experienced professional who has worked in various scientific roles at companies such as BIOCIUS Life Sciences, BioTrove, Agilent Technologies, and Momentum Biotechnologies. With a Ph.D. in Biochemistry, Toxicology, and DNA Damage from Massachusetts Institute of Technology, Peter has specialized in the development of RapidFire and LC separation methods, as well as QQQ and (Q)TOF mass spectrometry. Peter has a proven track record of conducting independent research efforts, managing projects, and publishing in peer-reviewed journals.
This person is not in any offices
Momentum Biotechnologies
Momentum Biotechnologies is a drug discovery partner that delivers innovative mass spec solutions to overcome research challenges for biopharma clients globally. Our core team of scientists and engineers started working together developing the RapidFire high-throughput MS platform and have been serving clients with MS-based services since 2004 including PureHoney Technologies (2015-23). Momentum Biotechnologies’ goal is to accelerate our partners’ drug discovery & development programs through superior mass spec based CRO services. We help clients identify and characterize leads for degraders, molecular glues, protein-protein interaction (PPI) disrupters, RNA binders and other target classes. We use innovative techniques including affinity selection MS (ASMS), intact mass MS, chemoproteomics and small & biomolecule analyses. We pride ourselves on rapid turnaround of the highest quality data, accelerating the momentum of our clients’ research projects. We have a large Mass Spec lab with 30+ instruments and a fully functional BL2 lab in Billerica, Massachusetts. For more information, please visit www.momentum.bio.